Juan Andres - 22 Oct 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
22 Oct 2021
Net transactions value
-$6,330,842
Form type
4
Filing time
26 Oct 2021, 17:13:14 UTC
Previous filing
22 Oct 2021
Next filing
29 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61,050 +5,000 $12.21* 5,000 22 Oct 2021 Direct F1
transaction MRNA Common Stock Sale $1,665,000 -5,000 -100% $333.00 0 22 Oct 2021 Direct F1
transaction MRNA Common Stock Options Exercise $2,531 +178 $14.22* 178 25 Oct 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61,050 +5,000 +2809% $12.21* 5,178 25 Oct 2021 Direct F1
transaction MRNA Common Stock Options Exercise $119,927 +9,822 +190% $12.21* 15,000 25 Oct 2021 Direct F1
transaction MRNA Common Stock Sale $4,910,400 -15,000 -100% $327.36 0 25 Oct 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -3% $0.000000 159,822 22 Oct 2021 Common Stock 5,000 $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -178 -0.26% $0.000000 68,629 25 Oct 2021 Common Stock 178 $14.22 Direct F1, F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -3.1% $0.000000 154,822 25 Oct 2021 Common Stock 5,000 $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -9,822 -6.3% $0.000000 145,000 25 Oct 2021 Common Stock 9,822 $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 This option is fully vested and exercisable.
F3 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer